Keywords: serono, raptiva, performs, well, ph, iii, psoriasis

Serono's Raptiva performs well in Ph III psoriasis study

Article | 03 July 2006

Print This

Swiss biotechnology group Serono says the data from a clinical study of Raptiva (efalizumab), the firm's psoriasis treatment, shows that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in